Cardioxyl制药公司募集2800万美元风险投资
- 互联网2012年11月14日 15:54 点击:1222
药物开发公司Cardioxyl,主要的产品是CXL-1020急性代偿失调心力衰竭复合药物。主要面向65岁以上的美国住院患者。
Cardioxyl Pharmaceuticals Raises $28 Million in Venture Funding
11/8/2012 9:07:45 AM
The drug development company’s lead product in its pipeline, CXL-1020is a compound designed to treat acute decompensated heart failure, the top reason for hospitalization among adults aged 65 or older in the US.The condition results in reduced cardiac function that typically results in fluid accumulation in the lungs (a condition called pulmonary edema) and severe shortness of breath, according to the company’s website. The therapeutic in Phase 2 developmentwaslicensed from Johns Hopkins University.It is designed to improve the performance of heart muscle contractions and widen the blood vessels to increase blood flow without increasing the heart rate. It also has three other cardiovascular disease therapeutics in preclinical development.
联系邮箱:kefu@labbase.net
版权与免责声明
- 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.labbase.net,违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
- 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。